title: Neuropsychiatric side effects of efavirenz therapy.
abstract: The non-nucleoside analogue inhibitor of the reverse transcriptase, efavirenz (EFV), has become commonly used in highly active antiretroviral combination therapy in the treatment of HIV infection. Although being effective in suppressing plasma viral load, neuropsychiatric side effects have been reported in individuals treated with EFV. There are early complications, such as acute psychosis resembling reactions to LSD intake, as well as nightmares occurring for several days up to 4 weeks after the start of therapy. Although LSD-like psychosis provokes the necessity of therapy discontinuation, the nightmares, as well as irritability and concentration problems in daily life, disappear after several weeks of treatment. Late complications are depressive episodes that must be carefully differentiated from pre-existing psychiatric disease and virus-induced brain damage. This review describes neuropsychiatric symptoms provoked by EFV, differential-diagnostic procedures and treatment options, and provides pro's and con's for EFV use in clinical practice with respect to drug safety.
authors: University Hospital of Duesseldorf, Department of Neurology, Germany. Gabriele.Arendt@uni-duesseldorf.de
authors: Gabriele
authors: G
authors: Arendt
authors: Dominique
authors: D
authors: de Nocker
authors: Hans-Juergen
authors: HJ
authors: von Giesen
authors: Thorsten
authors: T
authors: Nolting
mesh_terms: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced* / Q000378:metabolism / Q000523:psychology*; D009483:Neuropsychological Tests; D019829:Nevirapine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D010078:Oxazines / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D019829:Nevirapine; C098320:efavirenz